The possibility of Korea's new drug no. 15, Kanarb (active ingredient: Fimasartan), a hypertension drug, becoming a new global drug is growing.
Boryung Pharmaceutical Company took part in a meeting of the International Society of Hypertension, one of the world's largest societies, held in Seoul until September 29 as the main sponsor and held a total of five satellite sessions, engraving Kanarb into the doctors from all over the world.
Kanarb was verified as a quick and powerful hypotensive drug based on licensed clinical trials and phase four of the clinical trials carried out in Korea.
According to the results of a clinical test on 14,151 Korean patients, the drug reduced the systolic blood pressure (SBP) by 18.7mmHg, and diastolic blood pressure (DBP) by 9.7mmHg. In particular, the drug was effective in lowering blood pressure among all three groups: new patients who took Kanarb the first time, patients who took additional drugs, and patients who switched to Kanarb.
The drug was most effective in reducing blood pressure among new patients: SBP by 26.4mmHg and DBP by 13.9mmHg. It also reduced blood pressure by a double-digit figure in both the patients who took additional drugs and patients who had switched to Kanarb.
More than thirty research results on Kanarb have been released in Korea and overseas so far, but in the latest society meeting, various clinical evidence was presented as they distributed a collection of clinical articles on Kanarb.
The cost in taking part as the main sponsor was quite expensive, but the company showed that new Korean drugs could also draw attention by presenting clinical evidence at overseas society meetings just as the new drugs developed by multinational pharmaceutical companies.
A representative of Boryung said, "Doctors from all over the world visited the Kanarb exhibition booth installed at the meeting of the International Society of Hypertension, showing great interest in the drug."
Such actions were part of a plan to release Kanarb overseas.
Kanarb, which received approval in 2010, is Korea's first hypertension drug. The following year, the company signed a deal with Mexico's Stendhal: 6.6 million won for the license and the first overseas export contract of 16 million won for finished products over a period of six years. Such actions revved up the engine for overseas exports.
During the meeting of the international society, the company also signed a contract with its Latin American partner, Stendhal, for the Latin American license of Dukarb (Ingredients: Fimasartan, Amlodipin), a combination drug for hypertension and Tuvero (Ingredients: Fimasartan, Rosuvastatin), a combination drug for hyperlipidemia, which were recently approved in South Korea.
The company signed export contracts with 25 Latin American countries including Mexico, 13 countries in Southeast Asia, Russia, and China amounting to 27 million dollars in license fees alone, and 348 million dollars for the supply of the products, Kanarb, Kanarb Plus, Dukarb and Tuvero as of September this year.
The sales of Kanarb also stand out in the domestic market. After it was launched, prescription of the drug has steadily increased to 32 billion won in 2014 and to 35 billion won in 2015. The product has successfully secured its position in the domestic market and is also showing progress in overseas markets.
Boryung plans to use its success in the domestic and Latin American markets as a stepping stone and enter countries advanced in the pharmaceutical industry such as the U.S., Europe and Japan beginning with Latin America, followed by Southeast Asia and Russia.
The company is currently conducting clinical tests for approval in Europe and Japan and plans to receive a license within 2-3 years. In the U.S. the company has completed phase one of the clinical trials and is steadily making preparations to enter the market.
Kanarb is highlighted for it is a commercialized product being sold overseas, showing the possibility of a new Korean drug becoming a global product.
<© Korea Biomedical Review, All rights reserved.>